A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness-Reference-Cited by-同舟云学术

A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness

Published:2024-05 Issue: Volume:202 Page:113975
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Yoshino Takayuki^ORCID,Hooda Naushin^ORCID,Younan Diana^ORCID,Muro Kei,Shitara Kohei^ORCID,Heinemann Volker,O’neil Bert Howard,Herrero Fernando Rivera,Peeters Marc^ORCID,Soeda Junpei,Suh Mina^ORCID,Reichert Heidi,Mezzi Khalid,Fryzek Jon,Chia Victoria,Rehn Marko,Stintzing Sebastian^ORCID

Funder

Amgen Inc

Publisher

Elsevier BV

Reference27 articles.

1. Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data;Kirstein;Oncologist,2014

2. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer;Heinemann;Eur J Cancer,2016

3. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial;Heinemann;Lancet Oncol,2014

4. Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma;Rivera;Int J Colorectal Dis,2017

5. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial;Venook;JAMA,2017

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Letter Re: A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness;European Journal of Cancer;2024-08

2. A network meta-analysis of efficacy and safety for first-line and maintenance therapies in patients with unresectable colorectal liver metastases;Frontiers in Pharmacology;2024-07-26

3. Prospective, Observational Study of Aflibercept Use in Combination with FOLFIRI in Patients with Metastatic Colorectal Cancer: A Real-World Effectiveness Study;Cancers;2024-05-24